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Abstract
FoxP3+ Treg cells are believed to play a role in the occurrence of autoimmunity and in the determination of clinical
recurrences. Contradictory reports are, however, available describing frequency and function of Treg cells during
autoimmune diseases. We examined, by both polychromatic flow cytometry, and real-time RT-PCR, several Treg markers in
peripheral blood mononuclear cells from patients with multiple sclerosis (MS), an autoimmune disease affecting the central
nervous system. We found that Tregs, as defined by CD25, CD39, FoxP3, CTLA4, and GITR expression, were significantly
decreased in stable MS patients as compared to healthy donors, but, surprisingly, restored to normal levels during an acute
clinical attack. We conclude that Treg cells are not involved in causing clinical relapses, but rather react to inflammation in
the attempt to restore homeostasis.
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Introduction
Cells with immunosuppressive functions raise particular interest
in multiple sclerosis (MS) because of their potential role in
pathogenesis, determination of disease course, and their prospec-
tive use in therapy [1]. CD25+FoxP3+ T regulatory cells (Tregs)
have been initially characterized in experimental autoimmune
encephalomyelitis (EAE), the mouse model for MS. In EAE,
CD4+CD25+ cells have a clear-cut beneficial role, suppressing
cytokine production by myelin-specific pathogenic TH1 cells, and
their transfer into normal mice prior to immunization results in
decreased disease severity [2]. Furthermore, anti-CD25 treatment
of resistant B10S mice renders these mice susceptible to EAE [3].
In humans, controversial results have been published. Periph-
eral blood CD4+CD25+ Tregs, measured by flow-cytometry, have
been described variably as decreased [4], or normal [5,6] in MS
patients as compared to healthy controls. Even if normal in
frequency, however, Tregs in MS patients may not be normal in
function, as proposed by Viglietta et al. [7], finding that has been
questioned when defining Tregs with different markers [8]. The
issue of Tregs functionality is especially relevant since several
studies have shown that CD4+CD25+ Treg cells are increased in
inflammatory sites in autoimmunity (i.e. pancreatic islets in
diabetes, synovia of arthritic joints [9] and, recently, in CSF of
MS patients [10] raising the question of whether these cells are
functional at these locations. Established markers of Treg
functionality are lacking, however polymorphisms in Tregs
effector genes such as CTLA-4, GITR, FoxP3 have been linked
to susceptibility to autoimmune diseases in humans, including MS
[11,12]. Misleading and contradictory data on Tregs, may be due
to the ambiguous nature of the markers employed so far. In fact,
one of the first proposed Treg markers, CD25 - IL2 receptor’a-
chain [13,14]- is constitutively expressed by T regs but also by
activated conventional T cells, B cells and macrophages [15,16].
Even if depletion of CD4+CD25+ T cell population leads to
autoimmune disease in nude mice [17], recent findings show that
up to one-third of FoxP3+ cells in a naı¨ve mouse are CD252 and
will remain unaffected by anti-CD25 monoclonal antibody (mAb)
administration) [18,19,20]. FoxP3 is the X-linked transcription
factor of the Forkhead/winged-helix box family, more recently
proposed as Treg marker [21,22]. Its mutation leads to a fatal
autoimmune lymphoproliferative disease in both humans (IPEX
syndrome) and mice (scurfy mice) [23] [24], and FoxP3 was
demonstrated to largely control Tregs development and functional
capacity [25,26]. Recent studies, however, show that ectopic
expression of FoxP3 in mouse CD4+ T cells is not sufficient to
generate Tregs in vitro, and transient FoxP3 expression has been
demonstrated in recently activated T cells [24,27,28]. Treg
effector molecules, which contribute to the activation and
proliferation of these cells and tune their suppression ability,
such as CTLA-4 and GITR, are considered as Treg functional
markers. CTLA4 (Cytotoxic T-Lymphocyte Antigen 4) is a
CD28-family receptor expressed mainly on CD4+ T cells, that
inhibits T cell proliferation interfering with co-stimulatory signals
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[29,30,31,32,33,34]. It is constitutively expressed on a subset of
Tregs, but also on resting T cells. GITR (glucocorticoid-induced
tumour necrosis factor receptor), a member of the TNF receptor
superfamily, is a surface receptor molecule involved in inhibiting
the suppressive activity of Tregs. It is constitutively expressed in
Tregs at a higher level than in other T cells although recently
activated T cells can also upregulate GITR expression in humans
[17,35].
Two novel functional Tregs markers are CD39 and CD73,
ecto-nucleotidases present on the surface of lymphocytes which act
in concert to hydrolyzes ATP or ADP to 59-AMP and 59-AMP to
adenosine, a potent anti-inflammatory molecule [36,37]. In
humans they are expressed on antigen presenting cells, B cells
and on a subset of human Foxp3+ Tregs with potent immuno-
suppressive properties representing activated effector/memory-like
suppressor cells, namely TREM cells. Tregs from CD39-null mice
show impaired suppressive properties in vitro and fail to block
allograft rejection in vivo. Strikingly reduced numbers of CD39+
Tregs -but not of total Tregs- are found in the blood of patients
suffering of RR-MS [38], and, more recently, decrease of CD39+
Tregs has been associated to disease progression in HIV [39].
Finally, low expression levels of the IL-7 receptor CD127, have
been used to better define FoxP3+ Tregs, making of CD127 a
useful and widely used negative Treg marker [40].
We analyzed, in unfractionated peripheral blood mononuclear
cells, several different markers, namely CD25, FoxP3, CTLA-4,
GITR, and CD39, in the attempt to more precisely define Tregs
and to identify the pattern that best describes their modulation
during MS. We compared flow cytometry, as gold standard, and
real time RT-PCR, to validate the latter as a tool to be used in
clinical settings, to overcome the issues related to sampling live
cells for disease monitoring.
Materials and Methods
Patient characteristics
We enrolled 85 patients with a clinically definite MS - according
to revised McDonald’s criteria [41]- and a relapsing-remitting
course. [42], from four different Centers in Italy, (San Raffaele
Hospital, Milan; Tor Vergata, Rome; Santa Lucia Hospital,
Rome; San Camillo Hospital, Rome). The Study has been
approved by the Ethical Committee-HSR for the San Raffaele
Scientific Institute, the Ethical Committee of the IRRCCS
Fondazione Santa Lucia, the Ethical Committee Azienda
Ospedaliera San Camillo-Forlanini, and the Ethical Committee
of the Azienda ospedaliero - universitaria Ospedali Riuniti Foggia.
All patients have signed an informed consent before blood
withdrawal. Patients were between 18 and 52 years old, had a
disease duration from less than one year to 29 years, a relatively
mild neurological disability (EDSS,4.0) and MRI-findings typical
of MS (according to Barkhof’s criteria) [43] Patients with
concomitant severe diseases (neoplasm, respiratory, renal, liver
or cardiac failures), recurrent urinary or pulmonary infections, or
pregnant women, were excluded.
Forty-two MS patients were in a stable phase of their disease -
no relapse in the 6 months before sampling. The other 43 patients
– namely ‘‘relapsing MS’’- were enrolled while experiencing a
well-defined relapse (as judged by clinical assessment by a trained
neurologist), whose clinical onset was between 8 hours and 10
days. None of the patients had been treated with steroids or
immunosuppressive agents in the 3 months preceding the relapse.
Sixty-five gender and age-matched healthy controls, with no
previous history of neurological or autoimmune disease and not
concomitant infection or allergy access, were also enrolled in the
study.
Cell isolation, RNA extraction, and cDNA synthesis
PBMCs from venous blood have been separated by Ficoll
density centrifugation (Lymphoprep, Axis Shield, Oslo, Norway)
within 3 hours from withdrawal. Either stained for FACS analysis
or washed and resuspended in TRIzolH for RNA extraction: 1 ml
of TRIzolH Reagent (Sigma-Aldrich) was used per 106106 cells.
RNA was extracted following the manufacturer’s protocol. cDNA
has been synthesized from 3 mg of RNA using the kit Ready-to-go
(Amersham Biosciences) following the manufacturer’s protocol,
and Real-time PCR (RT-PCR) using pre-developed TaqmanTM
Assay Reagents (Applied Biosystems, Foster City, MA), has been
used to measure the mRNA levels of the following targets: CD4,
CD25, FOXP3, GITR, CTLA4, CD39 and the endogenous
control GAPDH (all primers by Applied Biosystems, Foster City,
MA). AU (arbitrary units) were calculated using the following
formula: 22DD CT = 22((CT target-CT endogenous)2D CT).
Polychromatic Flow Cytometric Analysis
The following antibodies were used: hCD4, hFoxP3, hGITR,
(eBioscience); hCD25, hCTLA4 (BD Biosciences); hCD39 (Milte-
nyi). Antibodies were used at predetermined optimal concentra-
tions. Dead cells were excluded from analysis using LIVE/
DEADH Fixable Dead Cell Stain Kit (Invitrogen). FACS analysis
was carried out on a FACSCanto, (BD Bioscience), or on a CyAn
(Beckam Coulter). Data were analysed using FlowJo software
(Treestar).
Suppression assay
Human mononuclear cells were isolated by Ficoll gradient
centrifugation (Pharmacia, Uppsala, Sweden). Human cells were
further sorted with a MoFlo high speed cell sorter (Beckman
Coulter), after staining for CD4, CD25 and CD39. Purity of sorted
cells was always above 90%. Data were analyzed using FlowJo
software (Treestar, Ashland, OR).
The CD4+CD25highCD39+ cell subset was tested in vitro for
suppression in co-cultures with proliferating autologous
CD4+CD25neg responder cells. In vitro suppression assays were
carried out in RPMI/10% FCS in 96-well V-bottom plates
(Costar, Corning, NY). CFSE-labeled (Invitrogen, Carlsbad, CA)
CD4+CD25neg responder cells (2.06104) were incubated with
titrated amounts of FACS-sorted CD4+CD39+ and 106104
irradiated (3000 rad) antigen-presenting cells (APCs) that were
T-cell-depleted with a-CD3 (T3D). Stimulation was carried out
with plate-bound a-CD3 (UCTH1; 10 mg/mL). After 5 days at
37uC, samples were acquired on a Cyan flow-cytometer (Beckman
Coulter) and data were analyzed using FlowJo software (TreeStar,
Ashland, OR) to assess cell proliferation.
Statistical Analysis
As the datasets did not conform to a normal distribution,
median percentage (6 inter-quartile ranges) and nonparametric
tests (Mann-Whitney) were used throughout. A probability value
,0.05 was considered statistically significant. Data were analyzed
with Prism (version) 5.0.
Results
CD4+CD25+CD39+T cells co-express typical Treg markers
CD4+CD25highCD39+ T cells are bona fide Treg cells, both those
from healthy donors and from MS patients, displaying prolifer-
ation suppressive ability in classical in vitro assays [38]. In
T Regulatory Cells in MS
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agreement with this model, when CD39+ T cells were compared
to CD392 negative T cells, we found increased levels of expression
of all Treg markers tested, namely Foxp3 (Fig. 1A), CTLA4
(Fig. 1B), and GITR (Fig. 1C).
Molecular Treg markers are elevated in MS patients
experiencing a clinical relapse
We used the above described Treg markers to interrogate, by
molecular means, PBMC samples of patients affected by relapsing-
remitting MS in a stable or acute phase of the disease. We found
that all markers studied were strikingly reduced in stable MS
patients as compared to healthy individuals. Surprisingly, we
found that CD25 (Fig. 2A), CTLA4 (Fig. 2B), GITR (Fig. 2C), and
CD39 (Fig. 2D), and foxp3 (Fig. 2E) mRNA levels were
significantly increased in PBMCs from MS patients experiencing
a clinical relapse, as compared to patients in a stable phase of the
disease.
Treg cells frequency is increased in MS patients
experiencing a clinical relapse
To confirm that the different levels of expression of Treg
markers in PBMCs of relapsing MS patients, as measured by
molecular means, is associated to a corresponding modulation of
the T cell population of interest, we performed polychromatic flow
Figure 1. CD4+CD25highCD39+ T cells express increased levels of Treg markers. FoxP3 (A), CTLA4 (B) and GITR (C) expression, as measured
by flow cytometry, are increased in CD4+CD39+, as compared to CD4+CD392 T cells, especially in the CD25high compartment.
doi:10.1371/journal.pone.0021386.g001
T Regulatory Cells in MS
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cytometric analysis on freshly isolated PBMCs from healthy donors
and MS patients in different phases of disease activity. Since CTLA4
and GITR staining display lower discriminating sensitivity, we used
CD39, FoxP3, and CD25 as previously described [38]. Indeed, stable
MS patients showed a significant reduction of Treg cells as compared
to healthy donors (Fig. 3A–B; Fig. 4A–C). Samples collected from
patients during an acute attack, as suggested by mRNA levels,
displayed restored levels of Treg cells, comparable to that observed in
healthy donors (Fig. 3B–C; Fig. 4A–C). We confirmed that
CD4+CD25highCD39+ T cells from MS patients in the acute phase
of the disease are indeed suppressive, as shown in Fig. 4 D–F, thus
suggesting that the T regulatory compartment is not functionally
compromised in patients affected by MS.
Longitudinally followed MS patients display increase
Treg markers if experiencing a relapse
We then analyzed by RT-PCR, RNA samples from 15
untreated MS patients that had been followed longitudinally for
14 months with bi-monthly sampling, constituting the placebo arm
of a clinical trial. While seven patients remained relapse-free
Figure 2. Treg markers are up-regulated in RR-MS patients experiencing clinical relapses. A–E. Clinically relapsing RR-MS patients
displayed increased PBMC mRNA levels for CD25 (A), CTLA-4 (B), GITR (C), CD39 (D), and foxp3 (E). We also found significantly lower levels of Treg
markers mRNA in stable RR-MS patients as compared to healthy controls (HC). Values are expressed as arbitrary units (AU). P values are indicated
(Mann-Whitney).
doi:10.1371/journal.pone.0021386.g002
T Regulatory Cells in MS
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during the follow-up period, 8 experienced on or more clinical
relapses. As shown in figure 4G, patients that were clinically active
during the follow-up displayed increased levels of the Treg marker
Foxp3 mRNA as compared to the group of patients with stable
disease, where the Foxp3 mRNA expression levels remained
steady (Fig. 4H).
Discussion
The starting point of the present work has been the observation,
in archival cDNA samples, that Foxp3 mRNA levels were
increased in patients experiencing a clinical relapse. Since
decreased or defective Foxp3+ Tregs have been causally linked
to relapse occurrence in several reports [4,7], this finding appeared
to be paradoxical. Recent literature has however questioned
Foxp3 as Treg marker, indicating that general T cell activation
implies transient Foxp3 expression [27,28]. The increase in Foxp3
mRNA levels in relapsing MS patients can thus be attributed to
increased Tregs or to increased T cell activation in broad terms. In
the attempt to better distinguish between these two hypotheses, we
used several different markers that have been linked to Tregs.
Using this pattern of Treg-associated markers, we confirmed the
observation of an apparent upregulation of the Treg compartment
Figure 3. FoxP3+CD39+ Treg cells are increased during acute MS. Scatter plots from three representative subjects, one healthy donor (HC; A),
a stable MS patients (B), and a patient experiencing a clinical re-exacerbation of MS (C) are shown, indicating that the FoxP3/CD39 double positive T
cell population (A, right panel) in the CD25high gate dramatically decreases during stable MS (B, right panel) and is restored during an acute attack (C,
right panel).
doi:10.1371/journal.pone.0021386.g003
T Regulatory Cells in MS
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Figure 4. Treg cells are increased during acute MS. The percentage of FoxP3+ cells in the CD4+CD25high gate is shown in (A) in healthy controls
(HC; n = 14), stable MS (n = 10), and acute MS (n = 8). The percentage of CD39+ cells in the CD4+CD25high gate is shown in (B) in HC (n = 44), stable MS
(n = 31), and acute MS (n = 32), and, similarly, the percentage of FoxP3+/CD39+ cells in the CD4+CD25high gate is displayed in (C) in HC (n = 13), stable
MS (n = 12), and acute MS (n = 11). Again, while Treg cells, as defined by these markers, were significantly decreased in stable MS patients and
restored during an acute attack. Lines represent median values, and P values are indicated where significant (Mann-Whitney). CD4+CD25highCD39+
regulatory T cells from an acute MS patient suppress T responder cell proliferation (E) in a dose dependent way (F), as measured by CFSE dilution
assay. Plots represent CFSE-labeled T responder cell proliferation in absence and presence of regulatory T cell (5:1) (E, F). A representative experiment
among three is shown. Treatment-free RR-MS patients (n = 15) were followed longitudinally every two months for 14 months (G–H), and divided
according to the occurrence of clinical relapses during the follow-up in stable (G), or relapsing (H) patients. PBMC foxp3 mRNA values, normalized on
CD4 and GAPDH mRNA, and expressed as arbitrary units (AU) are plotted.
doi:10.1371/journal.pone.0021386.g004
T Regulatory Cells in MS
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during disease activity in an autoimmune disease such as MS.
Contradictory data are present in the literature on the number and
function of Tregs in MS as compared to healthy donors,
supporting the general idea that there probably is no major
difference among T cells with suppressive functions that may
contribute to disease development. Furthermore, peripheral blood
is the only, but far from ideal, site to investigate. Considering
suppressive T cells as a homeostatic mechanism aimed at
controlling excessive immune activation, their secondary increase
during inflammatory phases of the disease becomes reasonable
and in accordance with previous observation describing them as
migrating to inflammatory sites along and at the same time with
other inflammatory cells [44]. We explored, at this point, the
potential for these molecules to become useful biomarkers of
disease activity. The fact that we found CD39, an ectonuclease
thought to mediate suppressive activity of Tregs [36,38], as one of
the most reliable markers, may indicate that active, suppressive
Tregs are indeed mobilized from secondary lymphoid organs as a
consequence of reactivation of inflammation in the target organs,
and increase in the blood when traveling to the CNS where they
attempt to dampen inflammation. We propose CD39+ Treg as
biomarkers for disease activity, but their validation is outside the
scope of this work and requires larger cohorts of patients.
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